COMMUNIQUÉS West-GlobeNewswire

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
03/12/2025
Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the [...]
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
03/12/2025
Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the [...]
BetaGlue Therapeutics étend son essai clinique en Italie après avoir obtenu l’autorisation du ministère de la Santé italien pour mener son étude clinique sur le cancer du pancréas localement avancé non résécable (uLA-PDAC)
03/12/2025
MILAN, 03 déc. 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (« BetaGlue » ou la « Société »), une société d’oncologie en phase clinique développant une solution innovante de radiothérapie pour le traitement ciblé [...]
Elevar Therapeutics Announces Publication of CARES-310 Study Final Analysis in The Lancet Oncology
03/12/2025
Phase 3 trial assessed the efficacy and safety of Elevar’s rivoceranib in combination with camrelizumab as a first-line therapy for uHCC The combination continued to show clinically meaningful survival improvement [...]
Carl H. Sharperson III Joins MATTER Board of Directors
03/12/2025
MINNEAPOLIS, MN , Dec. 03, 2025 (GLOBE NEWSWIRE) -- MATTER, a Minnesota-based global NGO, today announced the appointment of Carl H. Sharperson III to its Board of Directors. Sharperson currently serves as a Senior [...]
NMDP Hires New Philanthropic Leader to Accelerate Financial Giving and Research
03/12/2025
MINNEAPOLIS, Dec. 03, 2025 (GLOBE NEWSWIRE) -- NMDP SM , a global nonprofit leader in cell therapy, hired Jessica Kowal as chief philanthropy officer to lead the NMDP Foundation SM , which expands access to blood stem [...]
4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial
03/12/2025
Prospective-trial analysis published in the Journal of the National Cancer Institute predicts residual cancer burden from baseline H&E slides using fully automated, treatment predictive platform NEWTON, Mass., Dec. [...]
MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell (MPC)-based Tissue-Engineered Therapy Showing Clinically Meaningful and Statistically Significant Benefits in Stress Urinary Incontinence
03/12/2025
Zurich, Switzerland, December 03, 2025 – MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 ( NCT05534269 ) evaluating its novel [...]
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date
03/12/2025
STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Immuron New U.S. Department of Defense Award & Clinical Trial Update
03/12/2025
Highlights: New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and Shigella Uniformed Services University P2TD clinical study update MELBOURNE, Australia, Dec. 03, 2025 ( [...]
World Class Health Partners with GAM to Select and Directly Contract with Top Quality Surgeons
03/12/2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- World Class Health (“WCH”), a global leader in medically led Centers of Excellence (CoE) networks, today announces their strategic partnership with Global Appropriateness [...]
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
03/12/2025
Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours , significantly faster versus placebo (p<0.0001) All secondary efficacy endpoints met (p<0.0001), including End of Progression™ 1 [...]
OKYO Pharma Announces Chairman and Founder Acquires Shares
03/12/2025
LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an [...]
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
03/12/2025
RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino [...]
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
03/12/2025
Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered Treatments at [...]
Microbix & Seegene Mexico Collaborate to Improve Test Accuracy
03/12/2025
Making HPV Tests & Quality Assessment Products Available across Mexico MISSISSAUGA, Ontario and MEXICO CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life [...]
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
03/12/2025
As previously announced, low dose D-cycloserine has been associated with augmentation of the antidepressant and antisuicidal response achieved by Transcranial Magnetic Stimulation (TMS). NRx has amended its [...]
Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline
03/12/2025
Deal with Laboratoires Th é a representing a total value of up to $280 million including clinical, regulatory and commercial conditional milestones, commercial royalties, and development responsibility for Phase 3 [...]
Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting
03/12/2025
First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch Workshop CARLSBAD, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. ( [...]

Pages